Rational Design, Synthesis and Biological Evaluation of Novel Derivatives Based on in vivo Metabolism of Natural Product β-elemene

2018 ◽  
Vol 15 (8) ◽  
pp. 905-912 ◽  
Author(s):  
Renren Bai ◽  
Xiaokang Jie ◽  
Eric Salgado ◽  
Jian Sun ◽  
Yao Zhu ◽  
...  
Author(s):  
Asma D. Ambekari ◽  
Shrinivas K. Mohite

Series of novel substituted Synthesis of N-{[5-(substituted)-1,3,4-oxadiazole-2-yl] carbamothioyl} derivatives containing 1,3,4-oxadiazole moiety were synthesized by microwave as a green chemistry method and conventional method by using pyridine 3- carboxylic acid as a starting material. The structures of the synthesized compounds were characterized by physicochemical data, IR, Mass spectra and 1HNMR. All the newly synthesized compound screened for their antimicrobial and In-vivo and In-vitro Anti-inflammatory studies. Anti-inflammatory studies revealed that compound 4f showed significant in-vivo and in-vitro anti-inflammatory activity as well potent antimicrobial activity.


2019 ◽  
Vol 89 ◽  
pp. 102870 ◽  
Author(s):  
Yuyang Ding ◽  
Fei Tang ◽  
Xiaoqian Xue ◽  
Jinfeng Luo ◽  
Muzammal Hussain ◽  
...  

2002 ◽  
Vol 12 (3) ◽  
pp. 437-440 ◽  
Author(s):  
Laura Betti ◽  
Maurizio Botta ◽  
Federico Corelli ◽  
Monia Floridi ◽  
Paola Fossa ◽  
...  

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0259008
Author(s):  
Leandro da Costa Clementino ◽  
Guilherme Felipe Santos Fernandes ◽  
Igor Muccilo Prokopczyk ◽  
Wilquer Castro Laurindo ◽  
Danyelle Toyama ◽  
...  

Leishmaniasis is a neglected disease that affects 12 million people living mainly in developing countries. Herein, 24 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo evaluation of their antileishmanial activity. Compound 4f, a furoxan derivative, was particularly remarkable in this regard, with EC50 value of 3.6 μM against L. infantum amastigote forms and CC50 value superior to 500 μM against murine peritoneal macrophages. In vitro studies suggested that 4f may act by a dual effect, by releasing nitric oxide after biotransformation and by inhibiting cysteine protease CPB (IC50: 4.5 μM). In vivo studies using an acute model of infection showed that compound 4f at 7.7 mg/Kg reduced ~90% of parasite burden in the liver and spleen of L. infantum-infected BALB/c mice. Altogether, these outcomes highlight furoxan 4f as a promising compound for further evaluation as an antileishmanial agent.


Sign in / Sign up

Export Citation Format

Share Document